Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. AML patients showed early signs of benefit, but safety concerns led to an immediate stop. On August 14, 2025, Schrödinger announced it will halt development of its CDC7 inhibitor SGR-2921 after two treatment-related deaths in […]
The post Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths first appeared on 2 Minute Medicine.Source: 2 Minute Medicine